PT1328527E - Cefalotaxanos, seu metodo de preparacao e sua utilizacao no tratamento de cancros, leucemias e parasitas, incluindo aqueles resistentes aos agentes quimioterapeuticos habituais, e como agentes de inversao - Google Patents

Cefalotaxanos, seu metodo de preparacao e sua utilizacao no tratamento de cancros, leucemias e parasitas, incluindo aqueles resistentes aos agentes quimioterapeuticos habituais, e como agentes de inversao

Info

Publication number
PT1328527E
PT1328527E PT00969759T PT00969759T PT1328527E PT 1328527 E PT1328527 E PT 1328527E PT 00969759 T PT00969759 T PT 00969759T PT 00969759 T PT00969759 T PT 00969759T PT 1328527 E PT1328527 E PT 1328527E
Authority
PT
Portugal
Prior art keywords
alkyl
leukemias
parasites
cancers
preparation
Prior art date
Application number
PT00969759T
Other languages
English (en)
Portuguese (pt)
Inventor
Robin Jean-Pierre
Dhal Robert
Drouye Freddy
Marie Jean-Pierre
Radosevic Nina
Robin Julie
Souchaud Karine
Bataille Patricia
Original Assignee
Stragen Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stragen Pharma Sa filed Critical Stragen Pharma Sa
Publication of PT1328527E publication Critical patent/PT1328527E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT00969759T 2000-10-17 2000-10-17 Cefalotaxanos, seu metodo de preparacao e sua utilizacao no tratamento de cancros, leucemias e parasitas, incluindo aqueles resistentes aos agentes quimioterapeuticos habituais, e como agentes de inversao PT1328527E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2000/001593 WO2002032904A1 (en) 2000-10-17 2000-10-17 New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents

Publications (1)

Publication Number Publication Date
PT1328527E true PT1328527E (pt) 2006-06-30

Family

ID=11003995

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00969759T PT1328527E (pt) 2000-10-17 2000-10-17 Cefalotaxanos, seu metodo de preparacao e sua utilizacao no tratamento de cancros, leucemias e parasitas, incluindo aqueles resistentes aos agentes quimioterapeuticos habituais, e como agentes de inversao

Country Status (12)

Country Link
US (1) US6579869B1 (enExample)
EP (1) EP1328527B1 (enExample)
JP (1) JP4837233B2 (enExample)
CN (1) CN1303084C (enExample)
AT (1) ATE319714T1 (enExample)
AU (1) AU7940500A (enExample)
CA (1) CA2426103A1 (enExample)
DE (1) DE60026557T2 (enExample)
DK (1) DK1328527T3 (enExample)
ES (1) ES2258024T3 (enExample)
PT (1) PT1328527E (enExample)
WO (1) WO2002032904A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285546B2 (en) * 2000-10-17 2007-10-23 Stragen Pharma S.A. Cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including those resistant to usual chemotherapeutic agents and as reversal agents
US20020128258A1 (en) * 2001-03-09 2002-09-12 Jean-Pierre Robin Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives
WO2004009092A1 (en) * 2002-07-17 2004-01-29 Chemgenex Pharmaceuticals Limited Formulations and methods of administration of cephalotaxines, including homoharringtonine
US7642252B2 (en) 2002-07-22 2010-01-05 Chemgenex Pharmaceuticals, Inc. Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof
WO2009148654A2 (en) 2008-03-03 2009-12-10 Sloan-Kettering Institute For Cancer Research Cephalotaxus esters, methods of synthesis, and uses thereof
US20120022250A1 (en) * 2009-03-11 2012-01-26 Jean-Pierre Robin Process for preparing cephalotaxine esters
CN102304132B (zh) * 2011-07-12 2015-01-28 南开大学 高效高立体选择性半合成三尖杉酯类生物碱的方法
CN103687859B (zh) * 2011-08-18 2016-08-17 杭州本生药业有限公司 高三尖杉酯碱的胺化衍生物、及其制备方法和应用
CN102675327B (zh) * 2012-03-01 2014-12-10 南开大学 三尖杉酯碱类似物及制备方法和应用
CN104293855A (zh) * 2014-10-15 2015-01-21 中国计量学院 脐孢木霉菌转化株在提高木霉素产量中的应用
US10597401B2 (en) 2015-05-08 2020-03-24 Albany Molecular Research, Inc. Methods and intermediates for the preparation of omacetaxine and cephalotaxine derivatives thereof
CN106866690B (zh) * 2015-12-10 2019-10-11 南开大学 三尖杉酯类生物碱、其制备方法和用途
CN109111459B (zh) * 2017-06-22 2021-10-29 南华大学 含水杨酸三尖杉碱酯衍生物、制造方法及其用途
CN108378049A (zh) * 2018-05-02 2018-08-10 孙利嫚 一种含有粗榧生物碱和甲氧虫酰肼的农药组合物
TW202421631A (zh) * 2022-09-22 2024-06-01 南開大學 三尖杉酯鹼類衍生物及其藥物組合物、製備方法和用途
KR20250160078A (ko) * 2024-05-03 2025-11-11 주식회사 아론티어 암 연관 섬유아세포 표적용 약학 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2776292B1 (fr) * 1998-03-20 2004-09-10 Oncopharm Cephalotaxanes porteurs de chaine laterale et leur procede de synthese

Also Published As

Publication number Publication date
ES2258024T3 (es) 2006-08-16
EP1328527B1 (en) 2006-03-08
WO2002032904A1 (en) 2002-04-25
AU7940500A (en) 2002-04-29
DE60026557T2 (de) 2006-12-28
JP2004511560A (ja) 2004-04-15
US6579869B1 (en) 2003-06-17
CA2426103A1 (en) 2002-04-25
CN1474821A (zh) 2004-02-11
ATE319714T1 (de) 2006-03-15
DE60026557D1 (de) 2006-05-04
EP1328527A1 (en) 2003-07-23
HK1063183A1 (en) 2004-12-17
CN1303084C (zh) 2007-03-07
JP4837233B2 (ja) 2011-12-14
DK1328527T3 (da) 2006-07-17

Similar Documents

Publication Publication Date Title
AU7940500A (en) New cephalotaxanes, their method of preparation and their use in treatment of cancers, leukemias, parasites including thus resistant to usual chemotherapeutic agents and as reversal agents
EP0392376A3 (en) N-acyl derivatives of the ll-e33288 antitumor antibiotics
ATE324897T1 (de) Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern
NO883246D0 (no) Polyetylenglykolkarbaminat.
FR2359820A1 (fr) Antioxydants non migrateurs contenant un azide de sulfonyle
ATE320802T1 (de) Fettsäure-analoge zur behandlung von krebs
SE7706392L (sv) N-fosfonometylenmonoaminoalkanmono- och -polyfosfonsyror respektive n-fosfonometylendiaminoalkanpolyfosfonsyror samt sett for deras framstellning
EA200200810A1 (ru) Конденсированные соединения азола и их применение в качестве гипогликаемических агентов
ATE161254T1 (de) Benzopyranderivat
ES2031892T3 (es) Agentes antialergicos y antiinflamatorios.
ATE402168T1 (de) Heterocyclische topoisomerase toxine
FR2356626A1 (fr) Acides ureidoacetohydroxamiques substitues
ES417559A1 (es) Procedimiento de preparacion de compuestos ciclisados que llevan un grupo urea.
ES8602775A1 (es) Procedimiento para fotoestabilizar molsidomina
EP0750701A4 (en) Opaque means for paper
ES451134A1 (es) Procedimiento para la preparacion de nuevos compuestos hete-rociclicos conteniendo azufre.
ES8507527A1 (es) Procedimiento para producir derivados de tiatriazina
ES8603971A1 (es) Un metodo para el apresto y el lavado de tintes y-o estampa-dos en materiales textiles que contienen fibras de celulosa
ATE116856T1 (de) Prostacyclinderivate enthaltende mittel für die topische anwendung.
ATE384149T1 (de) Hydrophilieadditive
SE7708249L (sv) Sett att framstella en ny alkaloid av vinkamintyp och salter derav
NO20022913D0 (no) Vandig polyaminoamid og surfaktantsammensetning for papirfremstilling
ES522675A0 (es) Un compuesto de imidazolilpropanol opticamente activo.
NO305383B1 (no) Liktornpreparat
AR248401A1 (es) Un microbiocida de 3-halo-5-halometil-2-oxazolidinona, su preparacion e intermediario 5-halometil-2-oxazolidinona y control de un microorganismo en un sistema acuoso y sobre una superficie.